---
figid: PMC7143295__ijerph-17-02078-g004
figtitle: Mammalian target of rapamycin (mTOR) signaling pathway
organisms:
- NA
pmcid: PMC7143295
filename: ijerph-17-02078-g004.jpg
figlink: pmc/articles/PMC7143295/figure/ijerph-17-02078-f004/
number: F4
caption: Mammalian target of rapamycin (mTOR) signaling pathway. mTOR is a subunit
  of two distinct multi-protein complexes, mTORC1 and mTORC2. Both mTORC1 and mTORC2
  can be activated in response to growth-factors stimulation, whereas mTORC2 is a
  major kinase that phosphorylates and activates Akt. The importance of mTORC1 and
  mTORC2 in regulation of multiple cell functions vital for development of cancer
  and their strong interaction with oncogenic pathways make mTOR an attractive target
  for therapeutic intervention. The mechanisms of action of currently available mTOR
  inhibitors are shown. Reproduced with permission from Zaytseva YY, Valentino JD,
  Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Letters. 2012, 319,
  1–7 [].
papertitle: 'Triple-Negative Breast Cancer: A Review of Conventional and Advanced
  Therapeutic Strategies.'
reftext: Mauricio A. Medina, et al. Int J Environ Res Public Health. 2020 Mar;17(6):2078.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9459289
figid_alias: PMC7143295__F4
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC7143295__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7143295__ijerph-17-02078-g004.html
  '@type': Dataset
  description: Mammalian target of rapamycin (mTOR) signaling pathway. mTOR is a subunit
    of two distinct multi-protein complexes, mTORC1 and mTORC2. Both mTORC1 and mTORC2
    can be activated in response to growth-factors stimulation, whereas mTORC2 is
    a major kinase that phosphorylates and activates Akt. The importance of mTORC1
    and mTORC2 in regulation of multiple cell functions vital for development of cancer
    and their strong interaction with oncogenic pathways make mTOR an attractive target
    for therapeutic intervention. The mechanisms of action of currently available
    mTOR inhibitors are shown. Reproduced with permission from Zaytseva YY, Valentino
    JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Letters. 2012,
    319, 1–7 [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Mtor
  - Tor
  - Akt
  - Crtc
  - raptor
  - rictor
  - Act5C
  - Act42A
  - Act57B
  - Act79B
  - Act88F
  - Act87E
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - RPTOR
  - MAPKAP1
  - RICTOR
  - MLST8
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - Rapamycin
---
